Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Give One and Done? Evaluating a Change in Surgical Prophylaxis in Kidney Transplant Recipients.
K. Bliven, C. Truax, K. Snow, N. Kenyon, A. Carlson, S. Yeager, L. Smith.
Pharmacy, University of Utah Hospital and Clinics, Salt Lake City, UT.
Surgical-site infections (SSIs) occur in up to 11% of kidney transplant (txp) patients (pts). There is no consensus on the optimal peri-op prophylaxis regimen for…
2016 American Transplant Congress
Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.
M. Dokus,¹ A. Patel,¹ J. Iuppa,² E. Venniro,³ A. Danzig,¹ J. Cooley,² J. Taylor,³ R. Kashyap,¹ M. Orloff.¹
¹Department of Surgery, Division of Transplant and Hepatobiliary Surgery, University of Rochester, Rochester, NY; ²Department of Pharmacy, University of Rochester, Rochester, NY; ³Department of Medicine, Division of Nephrology, University of Rochester, Rochester, NY.
Background: Bleeding is a significant challenge after renal transplantation. Anti-thymocyte globulin (ATG) induced thrombocytopenia may increase bleeding after kidney transplantation (KTx), but this association has…
2016 American Transplant Congress
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.
A. Bushell,¹ J. van der Net,^1,2 D. Game,³ R. Hilton,³ S. Thirkell,⁴ P. Friend,² E. Geissler,⁵ K. Wood,¹ P. Harden,² G. Lombardi.⁴
¹Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; ²Oxford Transplant Centre, Oxford, United Kingdom; ³Guy's Hospital, London, United Kingdom; ⁴Immunoregulation Laboratory, King's College London, Guy's Hospital, London, United Kingdom; ⁵Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Introduction: The UK ONE Study trial investigates the safety and feasibility of regulatory T (Treg) cell therapy in renal transplantation.Materials and Methods: Eleven (9m;2f) living…
2016 American Transplant Congress
Understanding the Drivers Behind an Early Post-KAS Rise in Delayed Graft Function (DGF) Rates.
D. Stewart, A. Kucheryavaya, D. Klassen.
UNOS, Richmond, VA.
Background: DGF among solitary deceased donor kidney transplants (tx) increased by 22% (p<0.0001) -- from 24.6% to 30.1% -- during the first 6 months of…
2016 American Transplant Congress
Early Hospital Readmission Following Kidney Re-Transplantation.
E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Surgery, Johns Hopkins University, School of Medicine, Baltimore, MD.
BACKGROUND: Among first time kideny transplant (KT) recipients the incidence of early hospital readmission (EHR) is 31%. Kidney re-transplants are more complex and we hypothesize…
2016 American Transplant Congress
Seven Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients.
J. Leventhal,¹ J. Galvin,¹ D. Stare,¹ L. Gallon,¹ J. Miller,¹ J. Mathew,¹ M. Abecassis,¹ S. Ildstad.²
¹Northwestern University, Chicago; ²University of Louisville, Louisville.
36 subjects have been enrolled and 31 transplanted in a phase 2 protocol (IDE 13947) to induce tolerance in recipients of living donor renal allografts…
2016 American Transplant Congress
Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context.
N. Mooney,^1,2 A. Cross,^1,2 J. Lion,^1,2 A. Haziot,^1,2 D. Glotz.^1,2,3
¹INSERM UMRS 1160, Institut Universitaire d'Hématologie, Paris, France; ²Université-Paris-Diderot, Sorbonne Paris Cité, Paris, France; ³Service de Néphrologie et Transplantation, Hôpital Saint Louis, Paris, France.
This study examines the basic mechanisms by which high levels of circulating HLA class II donor-specific-antibodies can contribute to microvasculature damage in chronic antibody mediated…
2016 American Transplant Congress
Who Should Decide? Potential Living Kidney Donor Preferences for Making Decisions About Risk.
C. Thiessen,¹ J. Gannon,¹ K. Kennedy,² D. Dobosz,¹ S. Li,¹ D. Gray,³ A. Mussell,³ E. Gordon,² P. Reese,³ S. Kulkarni.¹
¹Yale U, New Haven; ²Northwestern U, Chicago; ³U Pennyslvania, Philadelphia.
BackgroundTransplant centers debate how to manage risks to potential living kidney donors (LKDs) when there is a lack of consensus about reasonable donor risk .We…
2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
A. Benitez,¹ T. Milford,² K. Torralba,³ K. Payne,² M. De Vera.¹
¹Transplantation Institute, Loma Linda University Health Care, Loma Linda, CA; ²Basic Science Division of Anatomy, Loma Linda University, Loma Linda, CA.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…
2016 American Transplant Congress
Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression.
M. Casey, T. Aijaz, X. Wen, S. Rehman, A. Santos, E. Thomas, K. Andreoni, K. Womer.
University of Florida, Gainesville, FL.
Introduction: HIV positive status is a well-known risk factor for acute rejection (AR) in kidney transplant recipients (KTR). In the United States, the majority of…